Navigation Links
NeurogesX CEO Anthony DiTonno to Retire by Year End
Date:4/29/2011

ary 1993 and also served as the Company's President and Chief Executive Officer from February 1993 through January 2008. Previously, Mr. Lyons held a number of senior management positions at Genentech, Inc. including Vice President of Business Development and Vice President of Sales, and had operating responsibility at Genentech Canada and Genentech Japan. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Vical Incorporated, Poinard Pharmaceuticals, and KaloBios Pharmaceuticals.  He was a former founding board member of Facet Biotech Corporation, which was sold to Abbott in April 2010. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and a Masters of Management from Northwestern University's J.L. Kellogg Graduate School of Management.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiar
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
2. NeurogesX to Present at J.P. Morgan Health Care Conference
3. NeurogesX to Present at Piper Jaffray Health Care Conference
4. NeurogesX Reports Third Quarter 2009 Results
5. NeurogesX to Present at Two November Conferences
6. NeurogesX to Present at UBS Global Life Sciences Conference
7. NeurogesX to Present at Upcoming Fall Conferences
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. NeurogesX Reports Second Quarter 2009 Results
10. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
11. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The Workgroup for Electronic Data ... use of health IT to create efficiencies in healthcare ... (HPID) Workgroup has developed an issue brief titled, ... Payer?” The HPID Workgroup, a part of WEDI’s Strategic ... for Medicare and Medicaid Services (CMS) to identify common ...
(Date:7/28/2014)... -- Research and Markets has announced the ... report to their offering. ... covers the designing and engineering of completely new biological ... of natural biological systems that provide improved and desirable ... extreme genetic engineering because it not only alters existing ...
(Date:7/28/2014)... 2014 Immunomic Therapeutics, Inc. (ITI) has ... develop potential treatments for glioblastoma multiforme (GBM), the most ... their patented vaccine platform, LAMP-vax. , The agreements, ... on the work of John H. Sampson, MD, PhD, ... Robert Tisch Brain Tumor Center at Duke University Medical ...
(Date:7/28/2014)... California (PRWEB) July 28, 2014 The ... 604.40 billion by 2020, according to a new study ... with the rising demand for effective vaccines and drugs ... with unmet medical needs is expected to drive market ... need to enhance agricultural productivity via the use of ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... Sciences Holdings, Inc. (OTC Bulletin Board: ... development and commercialization of novel drugs in the therapeutic ... that it has submitted a full proposal to the ... BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense .  It ...
... imaging system, scientists have tracked a group of near-infrared ... the body and out again, providing a description of ... could be used in developing therapeutic agents to treat ... of the health effects of air pollution. ...
... 2010 Financial Results ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
(Date:7/28/2014)... 2014) Rice University researchers are using magnetic beads ... that can be used as microscale models for polymer ... polymers, introduced as theory in the 1950s, can be ... should be of interest to materials scientists who study ... by Rice chemical and biomolecular engineer Sibani Lisa Biswal ...
(Date:7/28/2014)... , July 28, 2014 Research and ... "Biometrics Market in Latin America 2014-2018" report to ... Biometrics measure and analyze biological data. These ... irises, eye retinas, voice patterns, and hand measurements from ... more stored templates. The main purpose of a biometrics ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2Seeing is bead-lieving 2Biometrics Market in Latin America 2014-2018 2
... LANSING, Mich. A Michigan State University researcher ... Prize for the design of a low-cost, energy-efficient ... commercial spaces. Norbert Mϋller, assistant professor in ... John Barrie, of the Appropriate Technology Collaborative in ...
... (EPSCoR) has received $20 million in new funding from ... Regents for Higher Education. The combined $4 million ... years and enables Oklahoma EPSCoR to support research under ... Cellulosic Bioenergy." , Specifically, the funding supports a ...
... in order to survive? The answer changes depending on climate, ... new leaf sprouts. Stanford researchers have found that the ... word stoma, meaning mouth) is controlled by a specific signaling ... stomata development. The findings are described in a paper published ...
Cached Biology News:'Cool' idea for efficient climate control wins recognition 2Oklahoma EPSCoR receives $20 million for biofuels research 2Key link in how plants adapt to climate discovered by Stanford researchers 2
...
... Johnstone and M.W. Turner (1997). • ... methods used in the production of ... in immunoassays, the standardisation of antibodies ... including amplification systems, enzyme immunoassays for ...
... The 1-D PAGE ... Kit for Targeted Protein ... SDS PolyAcrylamide Gel Electrophoresis ... chemistry, and cleavable-linker technology ...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: